A 2017 study reported that CLK inhibition could modulate the alternative splicing of Mcl-1, an anti-apoptotic protein, and promote cancer cell death, suggesting a potential therapeutic approach for cancer treatment [101]. This evidence concerns the gene MCL1 and cancer.